Glaucoma filtering surgery combined with phacoemulsification in the era of new aqueous humor filtration devices: A systematic review.

Surv OphthalmolMay 6, 2026 (epub)
Clinical ResearchOphthalmology

Sieta Gassama, Paul Bastelica, Christophe Baudouin et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluates the efficacy and safety of combined glaucoma filtering surgeries with phacoemulsification (PCE) versus standalone procedures in 27 studies. The main outcome was surgical success at ≥ 12 months. Results indicate that combined surgeries generally provide comparable long-term efficacy and safety, although some standalone procedures may perform better under strict success criteria.

Key findings

  • Half of the studies comparing TRAB/PCE with standalone TRAB reported similar success rates.
  • Data for NPDS/PCE showed mostly equivalent outcomes compared to standalone NPDS.
  • XEN/PCE and PMS/PCE demonstrated similar surgical success rates and IOP reduction compared to standalone procedures.
  • Some subgroups and stricter outcome thresholds favored standalone approaches.

Why it matters

Understanding the comparative effectiveness of combined versus standalone glaucoma surgeries is crucial for optimizing patient outcomes and surgical decision-making in ophthalmology.

Source

PubMed · PMID 42103032

Published in Surv Ophthalmol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Ophthalmology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.